The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Subscribe To Our Newsletter & Stay Updated
